Navigation Links
Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/11/2010

BEDMINSTER, N.J., Nov. 11, 2010 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that Jerry Wisler, President and Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference at the St. Regis hotel in New York City on November 17, 2010 at  1:15pm Eastern time.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  The lead product candidate is Epanova, an Omega 3 fatty acid compound preparing to enter Phase III clinical development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL).  Future planned clinical trials for Epanova include patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy.  Omthera holds worldwide rights to Epanova.   For more information, please visit www.omthera.com.Media ContactRx Communications Group, LLCEric GoldmanVice President, Public Relations917-322-2563egoldman@rxir.com
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 A new independent ... is the proven ultraviolet-C (UV-C) disinfection solution of ... (HAIs). Published in the March ... Control , the peer-reviewed study of UV-C disinfection ... Vancouver General Hospital and Rochester General Hospital. According ...
(Date:3/22/2017)... -- FinancialBuzz.com News Commentary  ... According to a report by the New Frontier ... in 2016, and is projected to grow at a compound annual ... by 2025. The medical cannabis market is projected to grow at ... to an estimated $13.3 billion in 2025. These projections do not ...
(Date:3/22/2017)... , March 22, 2017 TFS is ... and Mr. Ed Tumaian , two global executive positions in ... be joining the Operational Leadership Team and will report to Dr. ... ... comes to TFS with 10 years of medical and scientific expertise ...
Breaking Medicine Technology:
(Date:3/22/2017)... MT (PRWEB) , ... March 22, 2017 , ... Schneider ... to families and business owners throughout the Yellowstone Valley region, is launching a charity ... only zoo and botanical garden in all of Montana State, and is home to ...
(Date:3/22/2017)... OH (PRWEB) , ... March 22, 2017 , ... ... provides asset protection services and financial planning assistance to communities throughout central Ohio, ... Traumatic Brain Injuries. , Estimates from the Department of Defense and the Veteran's ...
(Date:3/22/2017)... ... March 22, 2017 , ... HumanHaus is proud to ... The conventional broom was great when it was invented, but our customers today ... working parents, the social young couple, the empty nesters and retired that want to ...
(Date:3/22/2017)... ... ... Nearly a decade after it was first recommended that men over the ... to stir controversy. The US Preventative Services Task Force (USPSTF) issued a recommendation against ... news from a study published in JAMA Oncology suggests that more men ...
(Date:3/22/2017)... Las Vegas, NV (PRWEB) , ... March 22, ... ... provider of educational programs and training standards for eating disorder specialists and other ... is proud to announce the opening of its 31st annual iaedp Symposium at ...
Breaking Medicine News(10 mins):